Immunic (IMUX) Enterprise Value (2019 - 2026)

Immunic has reported Enterprise Value for 14 years, with the latest figure at -$186.6 million in Q1 2026.

• Quarterly Enterprise Value fell 1204.53% year-over-year to -$186.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$186.6 million (down 1204.53% YoY) and the FY2025 annual result came in at -$15.5 million, up 56.59% from the prior year.
• Enterprise Value fell to -$186.6 million in Q1 2026 per IMUX's latest filing, from -$15.5 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$14.3 million in Q1 2025 and troughed at -$186.6 million in Q1 2026.
• A 5-year average of -$72.5 million and a median of -$72.8 million in 2022 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value jumped 85.3% in 2025, then slumped 1204.53% in 2026.
• Over 5 years, Enterprise Value stood at -$116.4 million in 2022, then jumped by 59.89% to -$46.7 million in 2023, then gained by 23.58% to -$35.7 million in 2024, then soared by 56.59% to -$15.5 million in 2025, then slumped by 1105.19% to -$186.6 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$186.6 million, -$15.5 million, and -$35.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.